default author photo

Hiroshi Tanaka

Niigata Cancer Center Hospital

Kawagishimachi, Chuo-Ku

Niigata 951-8566

Japan

SCHOLARLY PAPERS

3

DOWNLOADS

101

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation-Positive NSCLC in Whom Systemic Disease (T790M-Negative) Progressed after Treatment with First- Or Second-Generation EGFR TKIS and Platinum-Based Chemotherapy

Number of pages: 19 Posted: 04 Jan 2023
Kindai University, Yamaguchi University, Sendai Kousei Hospital, National Cancer Center Hospital East, Saitama Cancer Center, Kanagawa Cancer Center, Juntendo University - Juntendo University Hospital, Niigata Cancer Center Hospital, Shizuoka Cancer Center, National Hospital Organization Nagoya Medical Center, Kobe University, Wakayama Medical University, Kindai University, Hiroshima University - Hiroshima University Hospital, Ehime University Graduate School of Medicine, Kyushu University - Kyushu University Hospital, Kurume University - Department of Internal Medicine, Japan Lung Cancer Alliance, Wakayama Medical University - Department of Pulmonary Medicine and Medical Oncology and Kindai University
Downloads 42 (1,157,785)

Abstract:

Loading...

lung cancer, EGFR, T790-negative, Osimertinib, Patient-initiated clinical trial

2.

A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients with Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring Met Exon 14 Alterations Who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial)

Number of pages: 11 Posted: 29 Aug 2024
Kindai University, Nara Medical University, Kyushu University - Kyushu University Hospital, Sendai Kousei Hospital - Department of Pulmonary Medicine, Juntendo University, affiliation not provided to SSRN, Niigata Cancer Center Hospital, National Hospital Organization Nagoya Medical Center, Kindai University, Hiroshima University - Hiroshima University Hospital, Ehime University and Yamaguchi University
Downloads 40 (1,183,237)

Abstract:

Loading...

Lung cancer, MET, acquired resistance, cabozantinib, clinical trial

3.

Adjuvant Chemotherapy Intensity and Prognosis in Completely Resected High-Grade Neuroendocrine Lung Carcinoma: A Post Hoc Analysis of JCOG1205/1206

Number of pages: 43 Posted: 22 Apr 2026
Kanagawa Cancer Center, Shizuoka Cancer Center - Division of Thoracic Oncology, National Cancer Center Hospital, Kansai Medical University, University of Tokyo - Department of Surgery, Hiroshima University, affiliation not provided to SSRN, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, Osaka City General Hospital, Niigata Cancer Center Hospital, affiliation not provided to SSRN, Dokkyo Medical University, National Cancer Center Hospital East - Department of Thoracic Surgery, National Cancer Center Hospital, affiliation not provided to SSRN, Kyushu University - Kyushu University Hospital and National Cancer Center Hospital - Department of Thoracic Surgery
Downloads 19 (1,470,786)

Abstract:

Loading...

high-grade neuroendocrine carcinoma, Small-cell lung cancer, large-cell neuroendocrine carcinoma, cisplatin, irinotecan, etoposide, Relative dose intensity